Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BioChaperone Insulin Lispro Dose-Response in T1D
NCT02146651Phase 2Completed
- Sponsor
- Adocia
- Start
- May 2014
- Primary completion
- Jul 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of insulin lispro in type 1 diabetes mellitus (T1D) (4 arms), sponsored by Adocia. Primary endpoints: Area Under the Curve Glucose Infusion Rate (0-last) at 12 hours, Maximum Glucose Infusion Rate at 12 hours and 2 more. Started May 2014; status: completed.
02
Drugs
insulin lispro
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02146651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02146651.